Top Ranked Momentum Stocks to Buy for February 21st

Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st:

CNA Financial Corporation (CNA): This provider of commercial property and casualty insurance products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.

CNA Financial Corporation Price and Consensus

CNA Financial Corporation Price and Consensus

CNA Financial Corporation price-consensus-chart | CNA Financial Corporation Quote

CNA Financial’s shares gained 10% over the last one month above the S&P 500’s increase of 1.6%. The company possesses a Momentum Score of A.

CNA Financial Corporation Price

CNA Financial Corporation Price

CNA Financial Corporation price | CNA Financial Corporation Quote

Electromed, Inc. (ELMD): This manufacturer of airway clearance therapy and related products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.

Electromed, Inc. Price and Consensus

Electromed, Inc. Price and Consensus

Electromed, Inc. price-consensus-chart | Electromed, Inc. Quote

Electromed’s shares gained 21.1% over the last one month. The company possesses a Momentum Score of A.

Electromed, Inc. Price

Electromed, Inc. Price

Electromed, Inc. price | Electromed, Inc. Quote

Pacira BioSciences, Inc. (PCRX): This provider ofnon-opioid pain management and regenerative health solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.

Pacira Pharmaceuticals, Inc. Price and Consensus

Pacira Pharmaceuticals, Inc. Price and Consensus

Pacira Pharmaceuticals, Inc. price-consensus-chart | Pacira Pharmaceuticals, Inc. Quote

Pacira BioSciences’ shares gained 12.4% over the last one month. The company possesses a Momentum Score of A.

Pacira Pharmaceuticals, Inc. Price

Pacira Pharmaceuticals, Inc. Price

Pacira Pharmaceuticals, Inc. price | Pacira Pharmaceuticals, Inc. Quote

Regeneron Pharmaceuticals, Inc. (REGN): This biopharmaceutical company carries a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.

Regeneron Pharmaceuticals, Inc. Price and Consensus

Regeneron Pharmaceuticals, Inc. Price and Consensus

Regeneron Pharmaceuticals, Inc. price-consensus-chart | Regeneron Pharmaceuticals, Inc. Quote

Regeneron Pharmaceuticals’ shares gained 9.7% over the last one month. The company possesses a Momentum Score of A.

Regeneron Pharmaceuticals, Inc. Price

Regeneron Pharmaceuticals, Inc. Price

Regeneron Pharmaceuticals, Inc. price | Regeneron Pharmaceuticals, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

More Stock News: This Is Bigger than the iPhone!                  

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. 

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
Pacira Pharmaceuticals, Inc. (PCRX) : Free Stock Analysis Report
 
Electromed, Inc. (ELMD) : Free Stock Analysis Report
 
CNA Financial Corporation (CNA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research